NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018

An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.

Read news story


NICE Talks podcasts

NICE Talks brings you the real life experiences of people working within the NHS, public health and social care.

You will hear the stories behind our work to improve care across the country through evidence-based guidance.

Press and media

Contact the press office: 07973 970 534 |